News Headlines Article

Online study of Avastin breast cancer patients
San Francisco Chronicle

South San Francisco’s Genentech has teamed up with personal genetics company 23andMe for a new kind of study – one that doesn’t require patients to find a clinical trial center or make frequent visits to a doctor’s office. The Bay Area companies are initiating an online effort to recruit 1,000 patients with metastatic breast cancer who have taken Genentech’s Avastin, a drug that had its approval for breast cancer revoked last year over safety and efficacy concerns.